IMS 2022 | DREAMM-9: The potential role of belantamab mafodotin in the frontline treatment of multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, highlights the potential use of belantamab mafodotin in the frontline treatment of patients with multiple myeloma, commenting on early data from the Phase I DREAMM-9 study (NCT04091126) evaluating belantamab mafodotin in combination with bortezomib, lenalidomide, and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma. According to Dr Cerchione, belantamab mafodotin could play a role in young and transplant-eligible patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
